Dendreon Corp.'s much-anticipated confirmatory Phase III trial of prostate cancer vaccine Provenge (sipuleucel-T) met its primary endpoint of improving overall survival, potentially ending the drug's two-year regulatory roller coaster ride and paving the way for the first FDA approval of a therapeutic cancer vaccine. (BioWorld Today) Read More
